Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J. et al, (2015), BJOG, 122, 843 - 849
B-cell depletion in immune thrombocytopenia.
Psaila B. and Cooper N., (2015), Lancet, 385, 1599 - 1601
Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.
Iskander D. et al, (2015), Blood, 125, 2553 - 2557
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Findlay JM. et al, (2015), Ann Oncol, 26, 624 - 644
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB. et al, (2015), J Clin Pharmacol, 55, 392 - 400
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
Scherber R. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 81 - 81
Decision theory and cost-benefit analysis of re-staging oesophageal cancer after neoadjuvant chemotherapy with PET-CT rather than CT
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 41 - 41
FDG-avid nodal stage of oesophageal cancer and response to neoadjuvant chemotherapy: new classifications predicting disease progression before surgery, and early recurrence afterwards
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 44 - 44
Off trial use of brentuximab vedotin in Hodgkin lymphoma - a regional experience
Browning JA. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 61 - 61
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J. et al, (2015), Ann Oncol, 26, 804 - 811
Rare, fulminant presentations of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma - a case series
Zhang XY. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 56 - 56
The impact of oesophageal cancer temporal heterogeneity on DNA markers, drivers and targets, and the development of a combined clinical, genomic, pathological and radiological framework
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 24 - 25
Clinical tumor staging of adenocarcinoma of the esophagus and esophagogastric junction.
Turkington RC. et al, (2015), J Clin Oncol, 33
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen J-L. et al, (2015), Int J Cancer, 136, E590 - E601
Identification of a Novel Mutation in MAGT1 and Progressive Multifocal Leucoencephalopathy in a 58-Year-Old Man with XMEN Disease
Dhalla F. et al, (2015), Journal of Clinical Immunology, 35, 112 - 118
O6.4VX-970, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein.
Asmal M. et al, (2015), Ann Oncol, 26 Suppl 2
Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
Rizzuto I. et al, (2015), Int J Gynecol Cancer, 25, 416 - 422
Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.
Dhalla F. et al, (2015), J Clin Immunol, 35, 112 - 118